JHLT OpenPub Date : 2026-11-01Epub Date: 2026-10-05DOI: 10.1016/j.jhlto.2026.100703
Yoseb Lee, Kitae Kim MD, Ah Ram Kim, Jung Ae Hong, Junho Hyun, Sang Eun Lee, Min-Seok Kim, Eun-Seok Jeon, Jin-Oh Choi, Jaewon Oh, Seok-Min Kang, Myoung Soo Kim, Jae-Joong Kim, Hae-Young Lee, Sung-Ho Jung, The KOTRY Study Group
{"title":"Sex-specific association between body mass index and mortality after heart transplantation: A nationwide KOTRY Cohort Study","authors":"Yoseb Lee, Kitae Kim MD, Ah Ram Kim, Jung Ae Hong, Junho Hyun, Sang Eun Lee, Min-Seok Kim, Eun-Seok Jeon, Jin-Oh Choi, Jaewon Oh, Seok-Min Kang, Myoung Soo Kim, Jae-Joong Kim, Hae-Young Lee, Sung-Ho Jung, The KOTRY Study Group","doi":"10.1016/j.jhlto.2026.100703","DOIUrl":"10.1016/j.jhlto.2026.100703","url":null,"abstract":"<div><h3>Background</h3><div>Body mass index has paradoxical associations with outcomes in advanced heart failure, but whether its relationship with survival after heart transplantation differs by sex remains uncertain.</div></div><div>Body mass index has paradoxical associations with outcomes in advanced heart failure, but whether its relationship with survival after heart transplantation differs by sex remains uncertain.</div><div><h3>Methods</h3><div>We analyzed 1059 adult heart transplant recipients enrolled in the Korean Organ Transplantation Registry from 2014 through 2023. Body mass index was assessed using Asian-specific BMI categories and 3-knot restricted cubic splines. The primary outcome was all-cause mortality. Multivariable Cox models adjusted for prespecified clinical characteristics and pretransplant support. Sex differences in the body mass index–mortality association were evaluated using restricted cubic spline modeling.</div></div><div>We analyzed 1059 adult heart transplant recipients enrolled in the Korean Organ Transplantation Registry from 2014 through 2023. Body mass index was assessed using Asian-specific BMI categories and 3-knot restricted cubic splines. The primary outcome was all-cause mortality. Multivariable Cox models adjusted for prespecified clinical characteristics and pretransplant support. Sex differences in the body mass index–mortality association were evaluated using restricted cubic spline modeling.</div><div><h3>Results</h3><div>The cohort included 304 female patients, and 217 deaths occurred during a median follow-up of 3.6 years. The body mass index–mortality association differed by sex in the pooled spline model (P for interaction=0.041). In male patients, the association was nonlinear and U-shaped (P for overall association=0.031; P for nonlinearity=0.017). Underweight was associated with higher mortality than normal weight (adjusted hazard ratio, 1.97; 95% confidence interval, 1.17–3.33). In female patients, the fitted association was inverse, without evidence of nonlinearity (P for overall association=0.030; P for nonlinearity=0.302). Obesity class I was associated with lower mortality than normal weight (adjusted hazard ratio, 0.24; 95% confidence interval, 0.08–0.73), although this estimate was based on few events.</div></div><div>The cohort included 304 female patients, and 217 deaths occurred during a median follow-up of 3.6 years. The body mass index–mortality association differed by sex in the pooled spline model (P for interaction=0.041). In male patients, the association was nonlinear and U-shaped (P for overall association=0.031; P for nonlinearity=0.017). Underweight was associated with higher mortality than normal weight (adjusted hazard ratio, 1.97; 95% confidence interval, 1.17–3.33). In female patients, the fitted association was inverse, without evidence of nonlinearity (P for overall association=0.030; P for nonlinearity=0.302). Obesity class I was associated with lower mortality tha","PeriodicalId":100741,"journal":{"name":"JHLT Open","volume":"14 ","pages":"Article 100703"},"PeriodicalIF":0.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13737392/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149345511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
JHLT OpenPub Date : 2026-11-01Epub Date: 2026-10-12DOI: 10.1016/j.jhlto.2026.100706
Najiya Fatma PhD, Suhani S. Patel MPH, Grace R. Lyden PhD, Nader Moazami MD, Brian Wayda MD, William F. Parker MD, MS, PhD, Sommer E. Gentry PhD
{"title":"Waitlist mortality risk (US-CRS score) distribution among status 1 and 2 adult heart transplant candidates with exceptions","authors":"Najiya Fatma PhD, Suhani S. Patel MPH, Grace R. Lyden PhD, Nader Moazami MD, Brian Wayda MD, William F. Parker MD, MS, PhD, Sommer E. Gentry PhD","doi":"10.1016/j.jhlto.2026.100706","DOIUrl":"10.1016/j.jhlto.2026.100706","url":null,"abstract":"<div><h3>Background</h3><div>The US-candidate risk score (US-CRS) predicts waitlist mortality among heart transplant candidates using 7 laboratory, cardiovascular, and cardiac device usage variables on a 50-point scale, with higher scores indicating greater mortality risk. We assessed whether US-CRS accurately assigns mortality risk for exception candidates, and whether the alignment of allocation priority with waitlist mortality risk (US-CRS) differs between candidates with and without exceptions.</div></div><div>The US-candidate risk score (US-CRS) predicts waitlist mortality among heart transplant candidates using 7 laboratory, cardiovascular, and cardiac device usage variables on a 50-point scale, with higher scores indicating greater mortality risk. We assessed whether US-CRS accurately assigns mortality risk for exception candidates, and whether the alignment of allocation priority with waitlist mortality risk (US-CRS) differs between candidates with and without exceptions.</div><div><h3>Methods</h3><div>We compared the performance of US-CRS in candidates with and without exceptions using receiver operating curves. We compared US-CRS distributions using the Kolmogorov-Smirnov (KS) test and examined the proportion of candidates below specific score thresholds in each group. We also compared candidates with and without exceptions using Wilcoxon Rank-Sum test for continuous variables and Pearson’s Chi-squared test or Fisher exact test for categorical variables.</div></div><div>We compared the performance of US-CRS in candidates with and without exceptions using receiver operating curves. We compared US-CRS distributions using the Kolmogorov-Smirnov (KS) test and examined the proportion of candidates below specific score thresholds in each group. We also compared candidates with and without exceptions using Wilcoxon Rank-Sum test for continuous variables and Pearson’s Chi-squared test or Fisher exact test for categorical variables.</div><div><h3>Results</h3><div>US-CRS is accurate for measuring mortality risk among exception candidates as it is among non-exception candidates. Patients with higher waitlist status had higher median US-CRS. However, the median US-CRS of Status 1 candidates without exceptions (50 [IQR 48–50]) was significantly higher than for candidates with exceptions (45 [36–48]; [<span><math><mrow><mi>p</mi><mo>≤</mo><mn>0.05</mn></mrow></math></span>]), and similarly for Status 2 (46 [41–49] vs. 42 [32–47]; [<span><math><mrow><mi>p</mi><mo>≤</mo><mn>0.05</mn></mrow></math></span>]). Notably, 33.13% of Status 1 and 41.28% of Status 2 candidates with exceptions had US-CRS below 40, compared to only 1.84% and 19.20% of candidates without exceptions, respectively. Conversely, among candidates in Status 3 and 4, candidates with exceptions generally had higher US-CRS than candidates without exceptions.</div></div><div>US-CRS is accurate for measuring mortality risk among exception candidates as it is among non-exception candidates. P","PeriodicalId":100741,"journal":{"name":"JHLT Open","volume":"14 ","pages":"Article 100706"},"PeriodicalIF":0.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149361141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
JHLT OpenPub Date : 2026-11-01Epub Date: 2026-10-12DOI: 10.1016/j.jhlto.2026.100702
Jonathan B. Edelson MD, Caroline S. O’Brien, Trent Leung, Debra Lefkowitz, Lakshmi Parvathinathan, Stephen Paridon, Sara King-Dowling, Jonathan A. Mitchell, Steven M. Kawut, Meghan Lane-Fall
{"title":"Increasing physical activity in pediatric heart transplant recipients: Insights from patients and their families to inform intervention design and implementation","authors":"Jonathan B. Edelson MD, Caroline S. O’Brien, Trent Leung, Debra Lefkowitz, Lakshmi Parvathinathan, Stephen Paridon, Sara King-Dowling, Jonathan A. Mitchell, Steven M. Kawut, Meghan Lane-Fall","doi":"10.1016/j.jhlto.2026.100702","DOIUrl":"10.1016/j.jhlto.2026.100702","url":null,"abstract":"<div><h3>Background</h3><div>Survival after pediatric heart transplantation (HT) remains limited, and recipients face a heightened burden of modifiable cardiovascular risk factors. Despite the well-established benefits of physical activity (PA), pediatric HT recipients demonstrate reduced exercise capacity and low participation in moderate-to-vigorous physical activity (MVPA). Effective interventions require a nuanced understanding of behavioral determinants influencing PA engagement. This study sought to characterize perceived barriers, facilitators, and intervention preferences among pediatric HT recipients and their caregivers using the Capability–Opportunity–Motivation Behavior (COM-B) framework.</div></div><div>Survival after pediatric heart transplantation (HT) remains limited, and recipients face a heightened burden of modifiable cardiovascular risk factors. Despite the well-established benefits of physical activity (PA), pediatric HT recipients demonstrate reduced exercise capacity and low participation in moderate-to-vigorous physical activity (MVPA). Effective interventions require a nuanced understanding of behavioral determinants influencing PA engagement. This study sought to characterize perceived barriers, facilitators, and intervention preferences among pediatric HT recipients and their caregivers using the Capability–Opportunity–Motivation Behavior (COM-B) framework.</div><div><h3>Methods</h3><div>We conducted semi-structured interviews with pediatric HT recipients aged 6–22 years and their caregivers at a single tertiary transplant center. Participants were purposively sampled to ensure variation in age at transplant, diagnosis, time since transplant, and prior exposure to PA interventions. Interviews explored current activity patterns, perceived barriers and facilitators, and preferences for structured exercise programs. Transcripts were analyzed using an integrated thematic approach combining a priori COM-B constructs with inductively derived themes.</div></div><div>We conducted semi-structured interviews with pediatric HT recipients aged 6–22 years and their caregivers at a single tertiary transplant center. Participants were purposively sampled to ensure variation in age at transplant, diagnosis, time since transplant, and prior exposure to PA interventions. Interviews explored current activity patterns, perceived barriers and facilitators, and preferences for structured exercise programs. Transcripts were analyzed using an integrated thematic approach combining a priori COM-B constructs with inductively derived themes.</div><div><h3>Results</h3><div>Thirty-four interviews were completed with 17 caregiver–patient dyads and one independent adult participant. Participants generally viewed PA as safe, enjoyable, and emotionally beneficial, reflecting strong intrinsic motivation and preserved psychological capability. Social influences—including peers, family members, and opportunities to connect with other transplant recipients","PeriodicalId":100741,"journal":{"name":"JHLT Open","volume":"14 ","pages":"Article 100702"},"PeriodicalIF":0.0,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149361148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Prognostic significance of atrial fibrillation resolution after left ventricular assist device implantation","authors":"Daisuke Yakabe, Kazuo Sakamoto, Komei Mizokami, Tsukasa Watanabe, Hirotake Yokoyama, Sayana Kuraoka, Kayo Misumi, Tomomi Nagayama, Keisuke Shinohara, Takeo Fujino, Toru Hashimoto, Shouji Matsushima, Akira Shiose, Kohtaro Abe","doi":"10.1016/j.jhlto.2026.100624","DOIUrl":"10.1016/j.jhlto.2026.100624","url":null,"abstract":"<div><h3>Background</h3><div>The clinical impact of atrial fibrillation (AF) in patients undergoing left ventricular assist device (LVAD) implantation remains uncertain, particularly regarding whether the post-LVAD rhythm status carries prognostic value.</div></div><div><h3>Methods</h3><div>We retrospectively reviewed consecutive LVAD recipients at our institution between 2008 and 2023. Patients were categorized as no AF, new-onset AF, resolved AF, or recurrent AF according to rhythm status before and after implantation. The primary endpoint was hospitalization for heart failure, and the secondary endpoints were all-cause death, stroke, and major bleeding. Left atrial (LA) reverse remodeling was quantified as the percent reduction in LA diameter.</div></div><div><h3>Results</h3><div>Among 115 patients (mean age 46 years; 69.6% male; 14.8% ischemic etiology), 44 (38.3%) had AF before implantation. Over a median follow-up of 50.8 months, 29 of 44 patients (65.9%) had no AF recurrence by 3 months after implantation (resolved AF group), whereas 15 had AF (recurrent AF group); among the 71 patients without pre-LVAD AF, three developed new-onset AF. Compared with the recurrent AF group, the resolved AF group had a significantly lower risk of heart failure hospitalization (hazard ratio, 0.25; 95% confidence interval, 0.07–0.86; P = 0.027). LA diameter decreased to a greater extent in the resolved AF group than in the recurrent AF group (LA reduction rate: 24.5% vs. 10.8%; P = 0.032).</div></div><div><h3>Conclusions</h3><div>LVAD implantation was associated with LA reduction through reverse remodeling and led to AF resolution in a subset of patients. Patients with AF resolution experienced fewer heart failure events during LVAD support.</div></div>","PeriodicalId":100741,"journal":{"name":"JHLT Open","volume":"13 ","pages":"Article 100624"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13393557/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148582002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
JHLT OpenPub Date : 2026-08-01Epub Date: 2026-06-26DOI: 10.1016/j.jhlto.2026.100615
Haruchika Yamamoto MD PhD, Aadil Ali PhD, Gabriel Siebiger MD, Elliot Wakeam MD, MPH, Laura Donahoe MD, Jonathan C. Yeung MD PhD, Andrew Pierre MD, Marc de Perrot MD, Kazuhiro Yasufuku MD, PhD, Thomas K. Waddell MD, Shaf Keshavjee MD MSc, Marcelo Cypel MSc, FACS, FRCSC
{"title":"Outcomes of lung transplantation using TorEx ex-vivo lung perfusion","authors":"Haruchika Yamamoto MD PhD, Aadil Ali PhD, Gabriel Siebiger MD, Elliot Wakeam MD, MPH, Laura Donahoe MD, Jonathan C. Yeung MD PhD, Andrew Pierre MD, Marc de Perrot MD, Kazuhiro Yasufuku MD, PhD, Thomas K. Waddell MD, Shaf Keshavjee MD MSc, Marcelo Cypel MSc, FACS, FRCSC","doi":"10.1016/j.jhlto.2026.100615","DOIUrl":"10.1016/j.jhlto.2026.100615","url":null,"abstract":"<div><h3>Purpose</h3><div>Ex-vivo lung perfusion (EVLP) has expanded donor lung utilization, with over 1000 cases performed at our center since 2008. A next-generation Toronto EVLP system (TorEx EVLP) was introduced in December 2022, enabling simplified circuit setup by loading an organ chamber into an all‑in‑one device, potentially facilitating EVLP use at less experienced centers. This study reports the initial experience with TorEx EVLP and compares outcomes with (1) first‑generation EVLP and (2) conventional lung transplantation without EVLP.</div></div><div><h3>Methods</h3><div>In this single-center retrospective cohort study, 1067 EVLP procedures were performed from September 2008 to September 2024 (first-generation EVLP [G1], n=874; TorEx EVLP [G2], n=193). Post-transplant short- and long-term outcomes were compared among G1, G2, and contemporaneous direct transplants without EVLP (direct, n=1575).</div></div><div><h3>Results</h3><div>Of 1067 EVLP cases, 684 were accepted for transplant (utilization: G1 64.4%, G2 62.7%), and 700 transplants were performed (including 16 split singles). G1 and G2 had significantly higher DCD donor use (direct vs G1 vs G2: 17% vs 48% vs 60%, p<0.001) and lower donor P/F ratios (422 vs 368 vs 368 mmHg, p<0.001). Recipients in G1 and G2 were older than direct recipients (59 vs 61 vs 65 years, p<0.05). Post‑transplant outcomes were similar across groups, including PGD3 at 72 h (15% vs 16% vs 10%, p=0.21), extubation within 72 h (65% vs 64% vs 68%, p=0.67), overall survival, and CLAD‑free survival.</div></div><div><h3>Conclusions</h3><div>Despite higher-risk donor use, outcomes with both first- and next-generation Toronto EVLP systems were comparable to direct transplantation.</div></div>","PeriodicalId":100741,"journal":{"name":"JHLT Open","volume":"13 ","pages":"Article 100615"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13396924/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148586505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
JHLT OpenPub Date : 2026-08-01Epub Date: 2026-06-30DOI: 10.1016/j.jhlto.2026.100620
Shahar Laks MD, Rebecca Pierce-Williams DO, Ngina Connors MD, Kelecia Brown MD, Jennifer Philips MD, Diane Holmes FNP-BC, Catarina Canha MD, Nicole Cyrille-Superville MD, Esther Kim MD, Monique Oye DO
{"title":"Cardiogenic shock in pregnancy: Prolonged axillary Impella 5.5 support during pregnancy and postpartum as bridge to heart transplantation","authors":"Shahar Laks MD, Rebecca Pierce-Williams DO, Ngina Connors MD, Kelecia Brown MD, Jennifer Philips MD, Diane Holmes FNP-BC, Catarina Canha MD, Nicole Cyrille-Superville MD, Esther Kim MD, Monique Oye DO","doi":"10.1016/j.jhlto.2026.100620","DOIUrl":"10.1016/j.jhlto.2026.100620","url":null,"abstract":"<div><h3>Background</h3><div>Cardiogenic shock during pregnancy carries substantial maternal and fetal morbidity and mortality, and guidance on temporary mechanical circulatory support (tMCS) in this setting remains limited.</div></div><div><h3>Case summary</h3><div>A 36-year-old woman at 21 weeks' gestation presented with severe dilated cardiomyopathy (ejection fraction 20%, LVIDd 8.0 cm), cardiogenic shock (cardiac index 1.7<!--> <!-->L/min/m²), and recurrent ventricular arrhythmias. She declined termination of pregnancy. An axillary Impella 5.5 was placed for hemodynamic stabilization with rapid improvement in cardiac output and filling pressures. Progressive ventricular arrhythmias at 23 weeks and 3 days necessitated urgent cesarean delivery; the neonate did not survive. The patient was supported with the Impella 5.5 for 66 days and underwent successful orthotopic heart transplantation.</div></div><div><h3>Discussion</h3><div>To our knowledge, this is one of the longest reported durations of Impella 5.5 support initiated during pregnancy and continued into the postpartum period. This case highlights important considerations that may inform individualized multidisciplinary decision-making on temporary mechanical circulatory support selection in pregnancy-associated cardiogenic shock.</div></div>","PeriodicalId":100741,"journal":{"name":"JHLT Open","volume":"13 ","pages":"Article 100620"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13396756/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148586633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
JHLT OpenPub Date : 2026-08-01Epub Date: 2026-07-06DOI: 10.1016/j.jhlto.2026.100619
M.A. Hu MD, Z.L. Zhang MD, R.F. Hoffmann PhD, C.T. Gan MD PhD, E.A.M. Verschuuren MD PhD, C. Van De Wauwer MD PhD, H.G.D. Leuvenink PhD, M.E. Erasmus MD PhD
{"title":"Eliminating circulating donor passenger leukocytes during clinical ex vivo lung perfusion does not attenuate inflammation","authors":"M.A. Hu MD, Z.L. Zhang MD, R.F. Hoffmann PhD, C.T. Gan MD PhD, E.A.M. Verschuuren MD PhD, C. Van De Wauwer MD PhD, H.G.D. Leuvenink PhD, M.E. Erasmus MD PhD","doi":"10.1016/j.jhlto.2026.100619","DOIUrl":"10.1016/j.jhlto.2026.100619","url":null,"abstract":"<div><h3>Purpose</h3><div>During Ex Vivo Lung Perfusion (EVLP), it is standard practice to incorporate a leukocyte filter to remove donor passenger leukocytes and attenuate their inflammatory effects. The widely used leukocyte filter, LeukoGuard 6, seems to be ineffective in reducing circulating leukocytes during EVLP. Therefore, we performed contemporary leukocyte filtration using BioR 02 plus leukocyte filters to reduce these leukocytes and investigate whether inflammation could be reduced.</div></div><div><h3>Methods</h3><div>EVLP was performed for a minimum of 180 min with 15 bilateral donor lungs. Perfusate samples were taken from the in- and outlet of the leukocyte filter, which was subsequently clamped after 60 min. Contemporary parallel leukocyte filtration was performed in 9 EVLPs (intervention group) and in 6 EVLPs without (control group).</div></div><div><h3>Results</h3><div>After EVLP, 6/6 donor lungs were transplanted in the control group and 6/9 in the intervention group. Leukocytes increased significantly from 30 to 180 min in the standard group compared with the intervention group. During EVLP IL-1, IL-6, IL-8, TNF-α, neutrophil elastase, CD-14, syndecan-1, hyaluronan and VCAM-1, levels were not significantly different between the groups at 90 and 180 min. Post-transplant, primary graft dysfunction (PGD) and 1-month survival were similar.</div></div><div><h3>Conclusion</h3><div>The intervention group showed significantly lower circulating donor passenger leukocytes. However, this did not lead to attenuated inflammatory cytokines, leukocyte activation, glycocalyx shedding or endothelial activation. Clinical outcomes were similar between groups. Further research is needed to determine the exact effect of these donor passenger leukocytes.</div></div>","PeriodicalId":100741,"journal":{"name":"JHLT Open","volume":"13 ","pages":"Article 100619"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13396920/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148586524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
JHLT OpenPub Date : 2026-05-01Epub Date: 2026-01-26DOI: 10.1016/j.jhlto.2026.100495
Enock Adjei MD , Blaine Sklar DNP, AGACNP-BC , John W. Stokes MD , Whitney D. Gannon MSN, MS , Amir Teimouri Dereshgi MD , Anil J. Trindade MD , Caitlin T. Demarest MD, PhD , Matthew Bacchetta MD, MBA , Konrad Hoetzenecker MD, PhD
{"title":"Rescuing lung transplant candidates with rapidly progressive interstitial lung disease who fail V-V ECMO: A case series of dual veno-arterial and veno-venous extracorporeal membrane oxygenation circuits","authors":"Enock Adjei MD , Blaine Sklar DNP, AGACNP-BC , John W. Stokes MD , Whitney D. Gannon MSN, MS , Amir Teimouri Dereshgi MD , Anil J. Trindade MD , Caitlin T. Demarest MD, PhD , Matthew Bacchetta MD, MBA , Konrad Hoetzenecker MD, PhD","doi":"10.1016/j.jhlto.2026.100495","DOIUrl":"10.1016/j.jhlto.2026.100495","url":null,"abstract":"<div><h3>Background</h3><div>Providing adequate, awake and ambulatory mechanical circulatory support to patients with rapidly progressive advanced intersitial lung disease (ILD) remains challenging. In a subset of ILD patients with refractory hypoxemia or hemodynamic instability, despite optimal veno-venous (V-V) extracorporeal membrane oxygenation (ECMO) support, the addition of a veno-arterial (V-A) ECMO circuit may avoid the need for mechanical ventilation and protect against right ventricular dysfunction and subsequent end-organ dysfunction.</div></div><div><h3>Methods</h3><div>We herein report the first case series of three patients with ILD who received dual VV-VA ECMO support as a bridge to transplantation.</div></div><div><h3>Results</h3><div>All patients survived until lung transplantation 2 to 8 days after V-A ECMO initiation and had an unremarkable post-transplant recovery.</div></div><div><h3>Conclusion</h3><div>Although the addition a second ECMO circuit is a complex and resource-intensive strategy, it is a feasible approach to stabilze a subset of ILD patients who are indequately supported with V-V ECMO.</div></div>","PeriodicalId":100741,"journal":{"name":"JHLT Open","volume":"12 ","pages":"Article 100495"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146190236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
JHLT OpenPub Date : 2026-05-01Epub Date: 2026-01-15DOI: 10.1016/j.jhlto.2026.100488
Yuriko Terada , Michael K. Pasque , Chad A. Witt , Ruben G. Nava , Benjamin D. Kozower , G. Alexander Patterson , Daniel Kreisel , Varun Puri , Ramsey R. Hachem , Tsuyoshi Takahashi
{"title":"Trends in primary graft dysfunction and early mortality following lung transplantation: A single center experience","authors":"Yuriko Terada , Michael K. Pasque , Chad A. Witt , Ruben G. Nava , Benjamin D. Kozower , G. Alexander Patterson , Daniel Kreisel , Varun Puri , Ramsey R. Hachem , Tsuyoshi Takahashi","doi":"10.1016/j.jhlto.2026.100488","DOIUrl":"10.1016/j.jhlto.2026.100488","url":null,"abstract":"<div><h3>Objectives</h3><div>Although the long-term prognosis after lung transplantation has improved recently, primary graft dysfunction (PGD) remains the major cause of early mortality. The aim of this study was to elucidate trends in PGD incidence and short-term mortality following lung transplantation in the contemporary era.</div></div><div><h3>Methods</h3><div>We analyzed a single-center database of lung transplantations performed across three periods (Era 1: 2009–2013, Era 2: 2014–2017, and Era 3: 2018–2021). PGD was graded according to the 2016 International Society for Heart and Lung Transplantation definition, and PGD grade 3 within T0–T72 was used as the primary outcome. Trends in PGD incidence, factors associated with PGD, and early mortality rates after lung transplantation were identified.</div></div><div><h3>Results</h3><div>This study included 856 lung transplants: 277 in Era 1, 296 in Era 2, and 283 in Era 3. PGD grade 3 incidence decreased significantly over time: 35.9% (99 cases) in Era 1, 26.4% (78 cases) in Era 2, and 18.4% (52 cases) in Era 3 (P<0.001). During the study period, the lung allocation score (LAS) and intraoperative cardiopulmonary bypass (CPB) use decreased, whereas the use of intraoperative nitric oxide and extracorporeal membrane oxygenation increased. Logistic multivariate modeling identified era, recipient sex (male), underlying disease, race, and blood transfusion as factors associated with PGD. No significant difference was observed in 30-day hospital mortality across the three eras (2.9%, 1.4%, and 1.4% for Era 1, Era 2, and Era 3, respectively; P=0.313).</div></div><div><h3>Conclusion</h3><div>This study demonstrated a significant reduction in PGD incidence over time, which coincided with a decrease in LAS and intraoperative CPB use. However, no significant changes were observed in short-term mortality after lung transplantation.</div></div>","PeriodicalId":100741,"journal":{"name":"JHLT Open","volume":"12 ","pages":"Article 100488"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146190240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
JHLT OpenPub Date : 2026-05-01Epub Date: 2025-12-17DOI: 10.1016/j.jhlto.2025.100470
Sarah Y. Park MD , Rocio Lopez MS, MPH , Michael J. Kirsch MD, MSCR , Elizabeth J. Bashian MD , Emily Hay-Arthur BA , Jack Zakrzewski MD , Jesse D. Schold PhD , Nicholas R. Teman MD , Jordan R.H. Hoffman MD, MPH , Michael T. Cain MD
{"title":"Heart transplantation graft survival following donation after circulatory death via thoracoabdominal normothermic regional perfusion","authors":"Sarah Y. Park MD , Rocio Lopez MS, MPH , Michael J. Kirsch MD, MSCR , Elizabeth J. Bashian MD , Emily Hay-Arthur BA , Jack Zakrzewski MD , Jesse D. Schold PhD , Nicholas R. Teman MD , Jordan R.H. Hoffman MD, MPH , Michael T. Cain MD","doi":"10.1016/j.jhlto.2025.100470","DOIUrl":"10.1016/j.jhlto.2025.100470","url":null,"abstract":"<div><h3>Background</h3><div>The impact of thoracoabdominal normothermic regional perfusion (TA-NRP) use in donation after circulatory death (DCD) on rates of graft survival after heart transplantation has yet to be established.</div></div><div><h3>Methods</h3><div>A cohort study of the Scientific Registry of Transplant Recipients was performed identifying all primary adult heart transplants performed in the United States between January 1, 2020, and May 31, 2024, comparing donation after brain death (DBD), DCD with direct procurement and perfusion (DPP) (defined as declaration of circulatory death to cross clamp <30 min), and DCD with TA-NRP (defined as declaration of circulatory death to cross clamp >40 min). The primary outcome was graft loss (re-transplant or death).</div></div><div><h3>Results</h3><div>There were 474 (3.5%) DCD TA-NRP, 899 (6.6%) DCD DPP, and 12,185 (89.9%) DBD heart transplants during the study period, with varying donor and baseline characteristics, including more male and non-Hispanic White DCD TA-NRP recipients, and fewer DCD TA-NRP recipients listed as Status 1. On multivariable analysis, graft survival rates did not significantly differ between cohorts [Adjusted Hazard Ratio (aHR) (95% CI): 0.98 (0.70, 1.37) for DCD TA-NRP vs. DBD; and 1.04 (0.69, 1.56) for DCD TA-NRP vs. DCD DPP].</div></div><div><h3>Conclusion</h3><div>DCD TA-NRP recovery in heart transplantation yields comparable rates of two-year graft survival compared to DCD DPP and DBD recovery, supporting greater utilization of TA-NRP recovery in DCD allografts.</div></div>","PeriodicalId":100741,"journal":{"name":"JHLT Open","volume":"12 ","pages":"Article 100470"},"PeriodicalIF":0.0,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146081933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}